ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new weapon in fight against aggressive blood cancer
Disease control OngoingThis early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combi…
Matched conditions: ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Can adding a pill to standard chemo beat aggressive blood cancer?
Disease control OngoingThis study is testing whether adding the drug lenalidomide to a standard chemotherapy combination works better for treating newly diagnosed aggressive lymphoma. About 350 patients with stage II-IV disease will receive either the standard treatment or the standard treatment plus l…
Matched conditions: ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC